HTN : RDN : NOW
Ready to Practice
An international resource for the adoption of Renal Denervation in the fight against Hypertension.
This channel aims to give hypertension specialists and GPs everything required to explore and deploy Renal Denervation in patient practice. Learn from RDN practitioners in your markets, in your own languages, with a range of scientific and practical information; and build collaborations with peers that sustain the successful use of this ground-breaking complimentary therapy.
This is channel is supported by an educational grant from Medtronic.
An international resource for the adoption of Renal Denervation in the fight against Hypertension.
This channel aims to give hypertension specialists and GPs everything required to explore and deploy Renal Denervation in patient practice. Learn from RDN practitioners in your markets, in your own languages, with a range of scientific and practical information; and build collaborations with peers that sustain the successful use of this ground-breaking complimentary therapy.
This is channel is supported by an educational grant from Medtronic.
Latest Updates
What do the guidelines say?
The guidelines upgraded Renal Denervation to class 2 , which means RDN can be used in certain patients with uncontrolled blood pressure
The guidelines help us improve our practice, to fight the major problem in hypertension management which is poor patient adherence
Safety, Significance, Sustainability
Among all trials, renal denervation has achieved relevant reductions in blood pressure against the background of an excellent safety profile
Patient selection
RDN:FDA | Patient Selection - An Interview with Dr. Taisei Kobayashi & Dr. Debbie Cohen
HTN:RDN
The consensus paper shows that the therapy works on the top of drugs, and in patients without drugs
Patient Preference – Shared Decision Making
We need to personalize the choice and to discuss case by case, what will be the best possible treatment
How to Start an RDN programme
HTN:RDN - A Documentary on Hypertension
ESH 2023. Key Takeaways from Key Opinion Leaders
Guidelines Update from ESH 2023
Totality of Evidence & The Science of RDN.
Patient Selection: Understanding the Patient Referral Pathway
ESC 2022
Clinical Trials & Research
RDN:Language Hubs
Long Term Efficacy and Safety of Renal Denervation
Hear from the experts on the latest ESH paper
Dr. Jose Antonio Garcia Donaire: The STEP trial showed a significant reduction in clinical events with similar levels of blood pressure reduction as RDN. What are the implications of RDN therapy?
HTN:RDN
Dr. Jose Antonio Garcia Donaire, discussing how recent data will help support his local consensus statement
HTN:RDN
FAQ's
What effect size should I expect from RDN, and what effect could that effect (reduction in blood pressure) have on cardiovascular morbidity and mortality?
HTN:RDN
Which evidence is most important to you to support the use of RDN in clinical practice?
HTN:RDN
EuroPCR Follow Up
Joachim Weil
What effect size should I expect from RDN, and what effect could that effect (reduction in blood pressure) have on cardiovascular morbidity and mortality?
HTN:RDN
Felix Mahfoud
Which is most the important method in reducing cardiovascular events: antihypertensive medication/RDN, or the successful maintenance of blood pressure reduction?
HTN:RDN
Atul Pathak
What effect size should I expect from RDN, and what effect could that effect (reduction in blood pressure) have on cardiovascular morbidity and mortality?
HTN:RDN
Pedro Gonçalves
How has the evidence base changed in support of RDN since the HTN 3 study was released?
HTN:RDN
Fausto Pinto
How has the evidence base changed in support of RDN since the HTN 3 study was released?
HTN:RDN
What effect size should I expect from RDN, and what effect could that effect (reduction in blood pressure) have on cardiovascular morbidity and mortality?
HTN:RDN
Jose Antonio Garcia Donaire
What effect size should I expect from RDN, and what effect could that effect (reduction in blood pressure) have on cardiovascular morbidity and mortality?
